Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Yupei Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7081-2299; OpenAlex author ID A5100302817, A5100357977. Sources: ClinicalTrials.gov.

Their work

Papers
112 (first author 0, last author 97)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
178
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 7 papers, 1 trial · 2015: 4 papers · 2016: 10 papers · 2017: 6 papers · 2018: 11 papers · 2019: 11 papers · 2020: 14 papers · 2021: 14 papers · 2022: 5 papers · 2023: 8 papers · 2024: 13 papers · 2025: 2 papers · 2026: 5 papers

Papers 50 of 112

  1. Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. Last author DOI 10.1016/j.canlet.2026.218558↗
  2. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  3. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Last author DOI 10.1038/s41392-026-02741-1↗
  4. Neutrophil extracellular traps induced by tumour-derived NGAL reprogram CAF subtypes via ITGA5 to promote tumour progression in pancreatic cancer. Last author DOI 10.1136/gutjnl-2025-337720↗
  5. [Expression of Concern] c‑Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. Last author DOI 10.3892/or.2026.9092↗
  6. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Last author DOI 10.1002/ctm2.70416↗
  7. Machine learning based identification of an amino acid metabolism related signature for predicting prognosis and immune microenvironment in pancreatic cancer. Last author DOI 10.1186/s12885-024-13374-4↗
  8. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Last author DOI 10.1002/jev2.12488↗
  9. Crosstalk between metabolic remodeling and epigenetic reprogramming: A new perspective on pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.216649↗
  10. Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.217117↗
  11. Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.217162↗
  12. Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gendis.2023.101143↗
  13. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer. Last author DOI 10.1038/s41698-024-00586-x↗
  14. Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer. Last author DOI 10.1097/jp9.0000000000000175↗
  15. Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis. Last author DOI 10.1128/spectrum.00962-24↗
  16. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Last author DOI 10.1186/s12943-024-02050-7↗
  17. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Last author DOI 10.1186/s12943-024-02184-8↗
  18. Comprehensive analysis of bulk and single-cell transcriptomic data reveals a novel signature associated with endoplasmic reticulum stress, lipid metabolism, an… Last author DOI 10.1186/s12967-024-05158-y↗
  19. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Last author DOI 10.1186/s13046-024-03201-w↗
  20. Construction of a novel model based on PVT1-MYC duet-related genes for predicting survival and characterization of the tumor microenvironment in pancreatic can… Last author DOI 10.3389/fimmu.2024.1435593↗
  21. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Last author DOI 10.1007/s13402-023-00836-3↗
  22. Early Detection of Pancreatic Cancer: Considerable Advances, but Still a Long Way to Go Last author DOI 10.1016/j.cgh.2023.08.022↗
  23. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway. Last author DOI 10.1038/s41419-023-05987-7↗
  24. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2023.08.035↗
  25. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  26. A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'. Last author DOI 10.1097/js9.0000000000000588↗
  27. A commentary on ‘Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection’ Last author DOI 10.1097/js9.0000000000000633↗
  28. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications. Last author DOI 10.1186/s13046-023-02698-x↗
  29. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Last author DOI 10.1002/mc.23420↗
  30. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. Last author DOI 10.1186/s12885-022-09927-0↗
  31. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in … Last author DOI 10.1186/s12885-022-09983-6↗
  32. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Last author DOI 10.3389/fonc.2022.965508↗
  33. Association between Temporal Glycemic Change and Risk of Pancreatic Cancer in Men: A Prospective Cohort Study. Last author DOI 10.3390/cancers14143403↗
  34. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Co-author DOI 10.1007/s00464-020-07938-1↗
  35. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Last author DOI 10.1007/s13238-020-00760-4↗
  36. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13402-020-00569-7↗
  37. Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.003↗
  38. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Last author DOI 10.1016/j.canlet.2021.06.027↗
  39. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Co-author DOI 10.1038/s43018-020-00134-z↗
  40. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  41. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Last author DOI 10.1186/s12935-021-01928-6↗
  42. Targeting hypoxic tumor microenvironment in pancreatic cancer. Last author DOI 10.1186/s13045-020-01030-w↗
  43. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Last author DOI 10.1186/s13045-021-01131-0↗
  44. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-021-02152-w↗
  45. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.709669↗
  46. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Last author DOI 10.3389/fimmu.2021.758004↗
  47. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.596573↗
  48. The enhancement of glycolysis regulates pancreatic cancer metastasis. Last author DOI 10.1007/s00018-019-03278-z↗
  49. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Last author DOI 10.1007/s00262-020-02542-7↗
  50. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Co-author DOI 10.1038/s41388-020-1260-1↗

Trials 1

  1. Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms Principal investigator NCT02125929↗

Closest collaborators

The 25 strongest of 178 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei You · 60 shared papers, 2012–2026 · strength 7.04
  2. Taiping Zhang · 47 shared papers, 2013–2026 · strength 4.72
  3. Gang Yang · 30 shared papers, 2017–2024 · strength 3.34
  4. Ruiyuan Xu · 12 shared papers, 2020–2024 · strength 2.32
  5. Bo Ren · 11 shared papers, 2020–2025 · strength 1.89
  6. Yuan Chen · 10 shared papers, 2020–2024 · strength 1.81
  7. Fangyu Zhao · 16 shared papers, 2018–2023 · strength 1.76
  8. Quan Liao · 17 shared papers, 2015–2024 · strength 1.73
  9. Jie Ren · 8 shared papers, 2023–2025 · strength 1.65
  10. Jiangdong Qiu · 13 shared papers, 2018–2026 · strength 1.59
  11. Menghua Dai · 13 shared papers, 2013–2026 · strength 1.51
  12. Jianlu Song · 8 shared papers, 2021–2024 · strength 1.47
  13. Rexiati Ruze · 8 shared papers, 2021–2024 · strength 1.47
  14. Jinshou Yang · 11 shared papers, 2019–2024 · strength 1.43
  15. Zhe Cao · 15 shared papers, 2014–2026 · strength 1.40
  16. Mengyu Feng · 15 shared papers, 2017–2021 · strength 1.34
  17. Qiaofei Liu · 11 shared papers, 2016–2024 · strength 1.23
  18. Xinpeng Yin · 6 shared papers, 2022–2024 · strength 1.17
  19. Chengcheng Wang · 5 shared papers, 2021–2024 · strength 1.14
  20. Jinxin Tao · 7 shared papers, 2021–2024 · strength 1.11
  21. Guangyu Chen · 8 shared papers, 2020–2023 · strength 1.04
  22. Wenhao Luo · 7 shared papers, 2019–2026 · strength 1.03
  23. Ming Cui · 8 shared papers, 2016–2025 · strength 0.98
  24. Wenming Wu · 9 shared papers, 2012–2026 · strength 0.95
  25. Yueze Liu · 8 shared papers, 2019–2023 · strength 0.90

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.